Previous 10 | Next 10 |
Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B Canada NewsWire CSL's HEMGENIX ® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis OTTAWA, ON ...
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delive...
2023-10-05 13:49:37 ET Shares of uniQure (NASDAQ: QURE) were up more than 8% as of 1 p.m. after rising as much as 14% earlier in the day. So far this year, the biotech stock is down more than 70%. The gene-editing therapy company said it plans to cut back staff and progr...
2023-10-05 07:59:37 ET More on uniQure uniQure: AMT-130 Data And Other Catalysts In H2 2023 uniQure: The AMT-130 Readout uniQure cleared to start U.S. trial for gene therapy Seeking Alpha’s Quant Rating on uniQure Historical earnings data for u...
~ Reduction of 28% of workforce not related to HEMGENIX ® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~ ~ Discontinuing investments in more than half of research and technology projects, centralizing op...
2023-10-04 17:50:03 ET Gainers: Prime Medicine ( NASDAQ: PRME ) +5% . uniQure ( QURE ) +5% . Aclaris Therapeutics ( ACRS ) +4% . ALX Oncology Holdings ( ALXO ) +3% . Aurora Innovation ( AUR ) +3% . Losers: MaxCy...
2023-09-21 14:37:34 ET More on uniQure Seeking Alpha’s Quant Rating on uniQure Historical earnings data for uniQure Financial information for uniQure uniQure: AMT-130 Data And Other Catalysts In H2 2023 uniQure: The AMT-130 Readout For ...
2023-09-07 06:50:56 ET Summary uniQure has made progress in advancing its gene therapy candidates, including AMT-130 for Huntington's disease; additional data from phase I/II study expected Q4 of 2023. Interim data from the phase I/II study of AMT-130 showed it was safe and tolera...
2023-09-05 13:10:58 ET Shares of uniQure (NASDAQ: QURE) were down more than 11% as of 1:06 p.m. on Tuesday after the gene-therapy company announced that the Food and Drug Administration (FDA) had cleared its investigational new drug (IND) application for AMT-260, a treatment for...
2023-09-05 10:38:09 ET More on uniQure Seeking Alpha’s Quant Rating on uniQure Historical earnings data for uniQure Financial information for uniQure uniQure: The AMT-130 Readout Biggest stock movers today: Patterson Companies, Peloton Interact...
News, Short Squeeze, Breakout and More Instantly...
uniQure N.V. Company Name:
QURE Stock Symbol:
NASDAQ Market:
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lob...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter fin...